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In this work silver nanoparticles were produced using tannic acid solution as reducing and capping agent. 
Results of UV-Vis and XRD ensured the existence of silver nanoparticles in the final samples. Nanoparticles 
with different morphologies were detected using FE-SEM micrographs. The antibacterial activity of the obtained 
silver nanoparticles was investigated against six bacteria strains (Gram-positive and Gram-negative) using Min-
imum Inhibitory Concentration (MIC) method. The results of MIC tests for these silver nanoparticles demon-
strated the inhibition of growth for most bacteria, including Klebsiella pneumonia, Bacillus subtilis, Acinetobac-
ter baumanii, Escherichia coli and Proteus mirabilis. 
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1. INTRODUCTION  
 
Silver nanoparticles are attracting a lot of attention 
in recent years, due to their wide applications in differ-
ent fields such as catalystic materials, information 
storage, fabrication of polymer composites and textile 
product with antibacterial properties. These nanoparti-
cles indicate great antibacterial activity against bacte-
ria, algae and fungi. As a result, they can be used for so 
many medical purposes [1-3]. Wound healing is one of 
the most well commonly used applications of silver na-
noparticles. Compared with other silver compounds, 
many studies have demonstrated the superior efficacy 
of silver nanoparticles in healing time, as well as 
achieving better appearance of the wounds after heal-
ing [4-5]. The antibacterial mechanism of silver nano-
particles is not completely comprehended. Yet, several 
studies propose that silver nanoparticles may react 
with or attach to the surface of the cell membrane and 
this will cause disturbance in permeability and vital 
functions of the cell. It is also possible that not only 
silver nanoparticles interact with the proteins and/or 
enzymes on the surface of membrane, but can also pen-
etrate inside the microorganism and cause dysfunction 
inside the cells. Moreover, due to the large surface area 
of nanoparticles, the smaller silver nanoparticles would 
have more interaction with bacteria and have more 
bactericidal effect [6-8]. 
Chemical reduction is the most common method for 
producing silver nanoparticles due to its convenience. 
In recent years, green chemistry methods for preparing 
silver nanoparticles with antibacterial properties have 
been proved to be far more suitable than other applied 
methods [9]. Many methods were employed to enhance 
green preparation of silver nanoparticles and investi-
gating their antibacterial activity, using natural com-
pounds and plant extracts, including edible mushroom 
extract [10] honey [11], Aloe vera plant extract [12], 
glucose in the presence of soluble starch as a stabilizing 
agent [13], Hibiscus leaf extract [14], Mimusops elengi 
leaf extract, [15], Millingtonia hortensis extract [16], 
Artocarpus heterophyllus seed extract [17], Mangifera 
indica extract [18], Cashew leaf [19], sucrose and 
maltose [20] and Macrotyloma uniflorum [21]. 
Tannic acid has a polyphenolic structure which en-
ables it to play the role of reducing agent and capping 
agent simultaneously, using numerous phenol groups 
and steric hindrance of the molecules.  
In this work, silver nanoparticles were produced as 
instructed in the work of Yi et al, [22] using tannic acid 
aquatic solution (as reducing and capping agent), for 
reducing silver nitrate at room temperature. Two types 
of morphology were detected using FE-SEM micro-
graphs. The antibacterial activity of the obtained silver 
nanoparticles was also investigated against six bacteria 
strains (Gram-positive and Gram-negative) using Min-
imum Inhibitory Concentration (MIC) method.  
 
2. EXPERIMENTAL 
 
2.1 Materials 
 
Silver nitrate (AgNO3, 99.9%), tannic acid 
(C76H52O46) and potassium carbonate (K2CO3) were 
used in synthesizing of silver nanoparticles. Ethanol 
was used as solvent for washing the precipitated nano-
particles (All materials purchased from Merck Chemi-
cals, Germany, and used without further treatments). 
All of the solutions were freshly made using de-ionized 
(D.I.) water (purchased from Zolal Company, Iran).  
The bacterial strains used in this study were 
Klebsiella pneumonia ATCC 700603, Bacillus subtilis 
ATCC 19659, Acinetobacter baumanii ATCC 19606, 
Peudomonas aeruginosa ATCC 27853, Escherichia coli 
ATCC 25922 and Proteus mirabilis ATCC12453, Which 
were supplied by Shahid Beheshti University of medical 
sciences (Tehran, Iran). All bacterial strains were grown 
and maintained on nutrient agar slants. Barium chloride 
(BaCl2) and Mueller-Hinton broth (Merck chemicals, 
Germany) was used to prepare micro dilution broth. 
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2.2 Methods 
 
Following studies of Yi et al [22] on synthesizing 
silver nanoparticles, the suitable pH value was report-
ed 7 for producing silver nanoplates. Therefore, since in 
this study, antibacterial use of these nanoparticles was 
considered, they were produced in aqueous media at pH 
value of 7, at room temperature. Synthesis was done as 
illustrated in Fig. 1 and in the complete absence of 
light.  
 
 
 
Fig. 1 – Different stages of the synthesis of the silver nanopar-
ticles. (A) Tannic acid solution, (B) after adding silver nitrate 
solution and (C) after adjustment of pH value using K2CO3 
 
Different concentrations of silver nitrate and tannic 
acid solutions were mixed in room temperature, in or-
der to obtain different particle sizes and morphologies 
(Table 1). This process was done using magnetic stir-
ring for four hours in a dark room. After that, the na-
noparticles were precipitated using centrifuge (RST16, 
D.T.A.P Co., Iran) with 4000 rpm for 30 minutes. The 
final nanoparticles were obtained after washing the 
precipitate twice with ethanol and homogenizing in D.I. 
water using ultrasound (400W Topsonic, Ultrasonic 
Technology Development Co., Iran) with 100 Watt pow-
er for 20 minutes. 
 
Table 1 – The recipe for Silver nanoparticle samples at pH 
value of 7 and room temperature 
 
 
X-ray Diffraction patterns (D8 ADVANCE, Bruker-
AXS, USA) confirmed the presence of silver crystals in 
obtained nanoparticles. UV-Vis spectrophotometer 
(JENWAY-6715, UK) was used for measuring the opti-
cal properties of final nanoparticles. Field emission 
scanning electron micrographs (Zeiss SIGMA/VP, Ox-
ford Instruments, UK) were studied to characterize the 
morphology and distribution of the final particles. 
 
2.3 Antibacterial Activity 
 
Minimum Inhibitory Concentrations (MICs) of the 
synthesized nanoparticles were measured against a 
range of Gram-positive (B.subtilis) and Gram-negative 
(K.pneumoniae, A.baumanii, P.aeruginosa, E.coli and 
P.mirabilis) bacteria. MICs were determined using the 
standard “two fold micro dilution method in Mueller-
Hinton broth” and antibacterial susceptibilities were 
reported according to CLSI (2013) guidelines [23]. 
To standardize the densityof inoculum for a suscepti-
bility test, a BaSO4 turbidity standard, equivalent to a 
0.5 McFarland standard should be used. A 0.5 ml frac-
tional solution of 0.048 mol/L BaCl2 (1.175 % w/v BaCl2. 
2H2O) was added to 99.5 ml of 0.18 mol/L H2SO4 
(1 % v/v) with constant stirring to maintain a suspen-
sion. The inoculum of 5105 CFU/ml was used for all MIC 
measurements and the MIC was taken as the lowest 
concentration of samples in the wells of the micro titer 
plate that showed no turbidity after 24 h at 37 ºC [18].  
 
3. RESULT AND DISCUSSION 
 
3.1 Characterizations 
 
Optical properties of the nanoparticles were investi-
gated using UV-Vis spectrum (Fig. 2). The surface 
plasmon resonance peak for silver nanoparticles at 420-
430 nm is clearly observed.  
 
 
 
Fig. 2 – UV-Vis spectrum of the samples showing the surface 
plasmon resonance peak for silver nanoparticles 
 
For further studies, XRD pattern along with FESEM 
micrographs were investigated. X-ray diffraction ensured 
the presence of silver crystals in synthesized particles. 
Fig. 3 shows the result for sample No. 1. The sample for 
XRD was prepared by drying the dispersed solution of 
nanoparticles in oven at low temperature (25 ºC, in order 
to inhibit sintering of the nanoparticles), after sonication 
in D.I. water. (1 1 1) peak at 38.7º, (2 0 0) peak at 43.5º, 
(2 2 0) peak at 65º and (3 1 1) peak at 78º are in complete 
consistency with silver crystals identification peaks. The 
peaks are attributed to the diffraction of (1 1 1), (2 0 0)  
Sample  
AgNO3 
(mM) 
Tannic Acid 
(mM) 
AgNO3/ 
 tannic Acid 
ratio 
No.1 5 0.25 20 
No.2 5 4 1.25 
A B 
C 
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Fig. 3 – X-ray diffraction spectrum. (1 1 1) peak at 38.7º, (2 0 0) peak at 43.5º, (2 2 0) peak at 65º and (3 1 1) peak at 78º 
 
and (2 2 0) planes of face-centered cubic (FCC) silver. 
The existence of (2 2 0) reflection indicates that the na-
noparticles are single crystals [19]. 
Field emission scanning electron microscopy was 
used in order to confirm the size of the silver nanoparti-
cles and determine their morphologies. The micrographs 
indicated narrow size distribution with particle size of 
10-20 nm (Fig. 4A) and also spherical morphology for 
sample No. 1 (Fig. 4B). In case of sample No. 2, FE-SEM 
micrographs indicated planar morphology. Fig. 5A shows 
these nanoplates or nanosheets with 150-800 nm width, 
and Fig. 5B specifies one of the nanoplates with width 
of approximately 600 nm, and other vertical plates with 
thicknesses less than 10 nm. 
The probable reason for this difference in morphology 
is the low concentration of tannic acid in the synthesis 
medium of sample No. 1, against the high concentration 
used for producing sample No. 2. Tannic acid molecules 
have large, branched structures which due to less 
possibility of steric hindrance in low concentration, gives 
them better access to silver nitrate molecules. As a 
result, reduction of silver nitrate is carried out faster and 
the yield of reduction is much higher.  
However, when the concentration of tannic acid is 
high, these large molecules cause extreme steric hin-
drance. Despite of the fact that same amount of silver 
nitrate was used in both samples, reduction of silver 
nitrate happens slowly and the process has lower yield 
than sample No. 1. This slow rate of reduction results 
in planar morphology. The steric hindrance of tannic 
acid molecules causes difficulty in controlling the parti-
cle size distribution and the final nano plates/sheets 
had width from 150 to 800 nm. 
 
3.2 Determination of MICs 
 
The previews works which studied the antibacterial 
activity of silver nanoparticles mostly used Kirby-
Bauer disc diffusion method. For example Guzmán et al 
studied silver nanoparticles produced by using 
hydrazine hydrate (reducing agent), sodium citrate 
(reducing and stabilizing agent) and sodium dodecyl 
sulphate (SDS) (also as stabilizing agent) at room 
temperature. The results demonstrated that the 
colloidal silver nanoparticles inhibited the growth of 
the tested bacteria, including methicillin-resistant 
Staphylococcus aureus (MRSA), S. aureus, E. coli and 
P. aeruginosa [26]. 
 
 
 
 
 
 
Fig. 4 – FE-SEM micrographs for sample No. 1, (A) narrow 
size distribution (B) spherical morphology of the nanoparticles 
 
Saravanan et al. also investigated the antibacterial ac-
tivity of silver nanoparticles which were synthesized using 
Mimusops elengi leaf extract as reducing and stabilizing 
agent. Outstanding antimicrobial efficiency was detected 
by clear zone of inhibition (Kirby-Bauer diffusion method) 
against K. pneumonia, M. luteus and S. aureus [15]. 
Bapat et al studied the same properties for the 
silver nano particles which were produced by using 
Artocarpus heterophyllus Lam. seed extract. The 
inhibition zones of agar diffusion method were reported 
for several Gram- positive (B. cereus, B. subtilis, 
S. aureus and S. typhomurium) and Gram- negative 
(P. aeruginosa and P. vulgaris) pathogenic bacteria. 
The results indicated no antibacterial activity against 
S. typhomurium and P. vulgaris [17]. 
A 
B 
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Fig. 5 – FE-SEM micrographs for sample No. 2, (A) planar 
morphology of the nanoparticles. (B) A nanoplate with width 
of approximately 600 nm 
 
MIC results for different concentrations of silver 
nanoparticle samples in the wells of the micro titer 
plate showed different turbidities after 24 h in 37 ºC. 
This haziness of the solution indicated the growth and 
multiplication of the bacteria. Both samples had 
acceptable results, but in case of P. aeruginosa there 
was no display of antimicrobial activity for both 
samples.  
Table 2 also demonstrates the minimum 
concentrations in which the bacterial growth was 
stopped, as fraction of concentration 1 which was 
100 g/ml for both samples. As reported in Fig. 6, 
sample No. 2 had the same MIC as sample No. 1, 
except in cases of K. pneumonia and B. subtilis. Sample 
No. 1, which had spherical morphology, showed better 
results in these two strains.  
As it was mentioned, the mechanisms of the 
bactericidal effect of silver nanoparticles against 
bacteria are not completely known. Inhibition of 
bacterial growth can be caused by interaction with 
surface of the cell membrane and disturbing its 
nutritional function such as permeability and 
respiration [27]. It is reasonable that the attachment of 
the particles to the bacteria would depend on the 
surface area of nanoparticle available for 
interaction/adsorption. Smaller nanoparticles with 
morphologies closer to spherical shape have larger 
surface area available for interacting with bacteria. As 
a result, they will have more bactericidal effect than 
the larger particles. 
The cell wall of Gram-negative bacteria is thinner 
than Gram-positive. The cell wall in Gram-negative 
bacteria composed of single or bi-layer Peptidoglycan 
while the cell wall of Gram-positive bacteria is 
composed of multiple layers of Peptidoglycan. This 
causes complications in diffusion and penetration of 
silver nanoparticles. Certainly the basic reason for 
antibacterial activity of the nanoparticles is release of 
silver cations from nanoparticles. Due to the toxicity of 
these cations for bacteria, their presence could change 
the permeability of the bacterial membranes, which 
would lead to their extermination [28]. Currently, 
silver nanoparticle based wound dressings are used in 
the clinics and these have been commonly used for 
many years with no reported systemic toxicity. As a 
result, it would seem that silver nanoparticles would be 
safe for humans to use at low doses [29]. 
 
4. CONCLUSION 
 
In this study, silver nanoparticles were produced us-
ing tannic acid aquatic solution for reducing silver ni-
trate at room temperature at pH 7. UV-Vis spectrum 
and XRD pattern ensured the existence of silver nano-
particles in final samples. Two types of morphology 
were detected using FE-SEM micrographs.  
Additionally the antibacterial activity of the 
nanoparticles was measured against Gram-positive and 
Gram-negative bacteria, using MIC method. The 
results demonstrated the inhibition of growth for most 
bacteria, including Klebsiella pneumonia, Bacillus 
subtilis, Acinetobacter baumanii, Escherichia coli and 
Proteus mirabilis. The lowest MIC of both samples 
were against E. coli and P. mirabilis in 3.12 µg/ml. 
Sample No.2 (with planar morphology) showed less 
antibacterial activity against K. pneumonia and B. 
subtilis. This could be due to the lower surface area of 
the nanoplates/sheets, and their larger width in two 
dimensions. But the nano spheres produced using 
nontoxic materials showed exceptional antibacterial  
 
Table 2 – The results for MIC test for bacteria strains 
 
 Bacteria Strain Gram nature 
MIC Sample No. 1  
(fraction of 1) (g/ml) 
MIC Sample No. 2 
(fraction of 1) (g/ml) 
K. pneumonia ATCC 700603 Negative 1/16 12.5 1/8 25 
B. subtilis ATCC 19659 Positive 1/16 12.5 1/8 25 
A. baumanii ATCC 19606 Negative 1/32 6.25 1/32 6.25 
P. aeruginosa ATCC 27853 Negative – – – – 
E. coli ATCC 25922 Negative 1/64 3.12 1/64 3.12 
P. mirabilis ATCC12453 Negative 1/64 3.12 1/64 3.12 
A 
B 
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Fig. 6 – Comparing the MIC results for sample No. 1 (green columns) and sample No. 2 (blue columns) 
 
activity because of their very high surface area and 
better ability to interact with bacteria. 
Using “green” materials for synthesizing these 
silver nanoparticles opens up the opportunities to use 
them for various biomedical applications such as 
hospital textile products or open wound dressings. 
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